Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MEETINGS - Conference entitled Blood Product Safety & Transmissible Spongiform Encephalopathies (US) February 2002:

This article was originally published in Clinica

Executive Summary

Cambridge Healthtech Institute's eighth annual Blood Product Safety & Transmissible Spongiform Encephalopathies conference will be held on February 4-7 2002 in Washington, DC. The first two days will focus on blood product safety and features lectures on implications of NAT testing for transfusion services, the EU system for licensing test kits, new therapeutic products and tissue safety regulations. The latter half of the event is dedicated to developments in diagnosing and screening for TSE, including cyclic amplification of protein misfolding. Both subjects are supported by poster displays and exhibits. Further information from Frederick Vargus on tel: +1 617 630 1300; fax: +1 617 630 1325; email: fvargus@healthtech.com

You may also be interested in...



Pandemic Response In US Consumer Health Market: OTC Pain Relief And Cough/Cold Purchases

Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.

venBio Raises $394m To Fund Biopharmas Through Human Proof-Of-Concept

Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.

FDA Wants To Put Hep C Tests On 510(k) Pathway

The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.

Topics

UsernamePublicRestriction

Register

MT074293

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel